SHOCKING! Eli Lilly Slashes Profit Forecast Amid Weight Loss Drug BOOM!
Eli Lilly, the mighty pharmaceutical giant, just dropped a bombshell! This powerhouse reported FIRST QUARTER results that blew previous estimates out of the water—but WAIT! There’s a twist: they’ve LOWERED their profit projections like a dramatic plot twist in a soap opera!
Weight Loss and Diabetes DRUGS SKYROCKET! But at What Cost?
Eli Lilly has revealed that its blockbuster weight loss and diabetes drugs are flying off the shelves, with earnings now expected to tumble between $20.78 and $22.28 per share—down from a promising $22.50 to $24! What’s behind this shocking revision? A staggering $1.57 BILLION charge linked to their recent cancer drug deal!
Sales Surge! But Will It Last?
Despite the ominous profit warning, the company maintains bold sales forecasts of $58 billion to $61 billion for fiscal 2025. With President Trump’s tariffs looming like a dark cloud, Eli Lilly claims they’ll endure!
In a fiery interview, CEO Dave Ricks asserts that the threat of tariffs is SENDING manufacturing back to the U.S.! Is this just political posturing, or is it a GAME-CHANGER for the drug industry?
Record-Breaking REVENUES for Mounjaro and Zepbound!
Hold on to your hats! Eli Lilly’s diabetes sensation, Mounjaro, raked in a jaw-dropping $3.84 billion—an unbelievable 113% increase from last year! Meanwhile, Zepbound has achieved SUPERSTAR status too, with sales soaring to $2.31 billion, MORE THAN QUADRUPLING its previous year! Analysts were left stunned as these titanic treatments defied expectations!
Trade Off: 5% STOCK PLUNGE!
But not everything sparkled—despite the incredible earnings, Eli Lilly’s stock took a nosedive, plummeting 5% in premarket trading.
QUICK LOOK: Eli Lilly’s First Quarter STUNNER!
Here’s the scoop:
- Earnings per Share: $3.34 (expected: $3.02)
- Revenue: $12.73 billion (expected: $12.67 billion)
With a whopping 45% revenue increase, the U.S. market is like a wildfire, jumping 49% to $8.49 billion!
Zepbound and Mounjaro: The HOTTEST Treatments!
Demand for Zepbound and Mounjaro is off the charts! Both drugs mimic gut hormones to suppress appetites and control blood sugar—facing a massive need that outstrips supply. The stakes are SO HIGH, Eli Lilly and rival Novo Nordisk are pouring BILLIONS into ramping up production!
The Food and Drug Administration has declared the shortage surrounding these treatments OVER—barring cheaper versions from pesky compounding pharmacies!
Stay Tuned for More DRAMA!
This story is still unfolding, and you won’t want to miss a single twist! Keep your eyes peeled for the latest updates on this explosive situation!
